TAKHZYRO: payments to doctors
Payments that named TAKHZYRO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.6M
- Providers
- 4,223
- Transactions
- 21,149
- Average per transaction
- $124
The per-transaction average — $124 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,223 providers the average total is $622, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $2,102,001 | 80.0% |
| Shire North American Group Inc | $525,632 | 20.0% |